secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2026-05-15T12:00:31+00:00
Accession:  0001493152-26-023344
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics Q1 2026 net loss $2.5M; cash burn concerns with only $1.5M left
--------------------------------------------------------------------------------

- Q1 2026 net loss narrowed to $2.5M vs $4.5M YoY; loss per share $0.23 (post reverse split).
- Cash and equivalents fell to $1.5M from $8.5M at Dec 2025; company needs to raise additional capital.
- R&D expenses dropped 82% to $0.5M due to Phase 1 clinical cost decrease and headcount reductions.
- Executive management transition underway; reassessing development priorities and Decoy platform.
- Preferred stock conversion completed during Q1 2026; all Series AA and AAA shares converted to common.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226023344/0001493152-26-023344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226023344/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer